What happened
GFC Life Science reported separate results for FY2025: revenue of US$12.2M (+5.42% year on year), operating profit of US$265K (−77.34% year on year) and net income of US$382K (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$12.2M |
|---|---|
| Revenue vs a year earlier | +5.42% |
| Operating profit | US$265K |
| Net income | US$382K |
| Period | FY2025 (separate) |
| Filed | 2026-02-11, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260211900671 → open original filing |
Source: DART. Information only, not investment advice.